HELP stock forecast, quote, news & analysis
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways... Show more
Why Helus Pharma (HELP) Stock Is Down -19% in the Last 30 Days
Key Takeaways
- Helus Pharma (HELP) shares have declined roughly 19% over the last 30 days, from about $11.70 in early October to near $9.45.
- The pullback follows a late-summer advance that carried the stock to roughly $14 in late August and early September.
- A leadership transition in late October, with co-founders stepping down from executive roles, coincided with renewed selling pressure.
- The lead candidate, HLP003, remains the key catalyst, with Phase 3 (APPROACH) topline data on track for the fourth quarter of 2026.
- Analysts have maintained constructive views, including Buy ratings with price targets well above current levels.
- Explore additional data on Price Targets, Earnings, and Forecast for deeper context on this ticker.
- For data-driven trading ideas across the market, explore Trending AI Robots.
Helus Pharma (HELP) Company Overview and Market Position
Helus Pharma Inc., formerly Cybin Inc., is a clinical-stage biopharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions. Its lead program, HLP003, is a deuterated psilocin analog in Phase 3 development for the adjunctive treatment of major depressive disorder (MDD) and holds FDA Breakthrough Therapy designation. A second candidate, HLP004, a deuterated DMT molecule, is in Phase 2 for generalized anxiety disorder (GAD). The company operates in Canada, the United States, the United Kingdom, and Ireland, and investors follow the stock primarily for its late-stage clinical catalysts and the growing regulatory acceptance of psychedelic-based therapeutics.
Helus Pharma (HELP) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, HELP has fallen approximately 19%, declining from a closing price near $11.70 in early October to roughly $9.45. The move has been uneven, with several lower-volume rebounds giving way to renewed selling pressure through mid- and late October.
The broader quarterly picture is similar. Shares climbed toward $14 in late August and briefly spiked to an intraday high above $15 in mid-September before reversing. From early-August levels near $11.60, the stock is now down roughly 19%, meaning the past three months have largely round-tripped a summer rally rather than building on it.
What Drove HELP Stock Price in the Last 30 Days
The 30-day decline does not trace to a single negative catalyst but rather to a combination of factors. On October 1, the company completed its legal name change from Cybin Inc. to Helus Pharma Inc., and on October 15 it appointed CNS drug-development veteran Dr. Suresh Durgam to its board. On October 21, management hosted an investor presentation reaffirming that topline data from the APPROACH Phase 3 study of HLP003 remains on track for the fourth quarter of 2026.
The most notable development was the October 27 announcement that co-founders Eric So and Paul Glavine would step down from executive roles while remaining on the board, with Mark Lawson appointed independent Chair. Leadership transitions at pre-revenue biotechs often weigh on sentiment, and the news coincided with further weakness. The decline also appears to reflect profit-taking after the September spike and cautious pre-catalyst positioning ahead of the Phase 3 readout, within a volatile small-cap biotech sector.
What Drove HELP Stock Performance Over the Last Quarter
Over the trailing three months, HELP's narrative has been shaped by progress toward late-stage data rather than by fundamental deterioration. A spring 2026 White House Executive Order that could prioritize FDA review of psychedelic therapies with Breakthrough designation provided a favorable regulatory backdrop, and the company reported its fiscal-year results alongside a completed $50 million underwritten offering in June. The APPROACH study surpassed 88% enrollment with topline data expected in the fourth quarter, and a Phase 2 readout for HLP004 in GAD showed improvement on the Hamilton Anxiety Rating Scale. Despite these milestones, the stock gave back its gains as investors adopted a more defensive stance ahead of the pivotal data.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant strategies appear in its curated Trending AI Robots section. These bots vary in strategy, timeframe, and performance metrics, giving traders a range of approaches to evaluate. The section is designed to highlight the bots that are currently generating the strongest signals across the market. Investors interested in systematic, data-driven trading can review the selection to see which strategies align with their own objectives and risk tolerance.
HELP Stock Forecast Drivers: What Investors Should Watch Next
The most important upcoming catalyst is the fourth-quarter 2026 topline readout from the APPROACH Phase 3 study of HLP003 for MDD, along with related data from the EMBRACE study. Progress on HLP004 in GAD, cash runway and any future financing, and the continued execution of the leadership transition will also be closely watched. Regulatory developments around psychedelic-based therapies and analyst expectations ahead of the data could drive volatility. As always with clinical-stage companies, trial outcomes remain uncertain, and investors should monitor these milestones rather than assume any specific result.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for HELP turns negative, indicating new downward trend
HELP saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 11 similar instances where the indicator turned negative. In 10 of the 11 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for HELP turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 7 similar instances when the indicator turned negative. In 4 of the 7 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HELP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for HELP entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HELP's RSI Indicator exited the oversold zone, 4 of 4 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 7 of 8 cases where HELP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +11.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where HELP advanced for three days, in 45 of 49 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
HELP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. HELP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.704) is normal, around the industry mean (3.498). P/E Ratio (-2.207) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HELP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology